אתר זה משתמש בקובצי Cookies כדי להבטיח שתקבל את החוויה הטובה ביותר באתר שלנו. קראו את מדיניות הפרטיות ותנאי השימוש.

המרכז האקדמי לב - קישור לדף הבית
ניגודיות גבוהה
רישום מקוון למידע נוסף

שאלות נפוצות

Ori Braitbard

Ori Braitbard

Ori Braitbard

  • Cancer, anti-cancer drugs, MMTV, immunotherapy, chemotherapy

    • Vaccination against lymphoma and breast cancers (with Prof. Jacob Hochman, Dept. of Cell and Developmental Biology, Hebrew University of Jerusalem, Israel).
    • Developing novel approaches toward reversal of multi-drug resistance in cancer. 
    • Biological Applications of Ti(IV) Complexes (with Prof. Edit Y. Tshuva –  Institute of Chemistry, Hebrew University of Jerusalem, Israel).
    • Vaccination against MMTV associated breast cancer

    Mouse Mammary Tumour Virus (MMTV) is a type B retrovirus associated with mammary carcinoma and lymphoma in laboratory mice. An increasing body of evidence in recent years supports an involvement of MMTV in about 37% of human breast cancers.

    These findings suggest the use of p14 (the SP of MMTV) for vaccination and passive immunization against malignant cancers that harbor MMTV.

    • Biological Applications of Ti(IV) Complexes

     

    Ti(IV) complexes are promising anti-cancer agents showed high cytotoxic activity toward numerous cancer cell lines (NCI-60) and high stability in aqueous environment.

    We examine the correlation between the complex properties: structure, hydrolytic stability and cytotoxicity in vitro and in vivo, revealing insights on the biological mechanism of their cytotoxicity, suggesting an apoptotic cell death pathway.

  • Potential Applications:

    • Kit(s) for diagnosis of p14 and p14 antibodies (in sera, biopsies and histological sections).
    • Preventive vaccination against MMTV-associated breast cancer
    • Humanized monoclonal anti-p14 antibodies for passive immunization.
    • Anti-cancer immune-conjugates for targeted drug delivery.
    • Isolation of p14-specific T-cells for Adoptive cell transfer
    • Analysing the genome (DNA chips of RNA seq) and proteome (protein profiling) data of p14 mutant and naïve cells.
    • Development of a new class of Titanium compounds as anti-cancer drugs

  • Prof. Jacob Hochman –  Dept. of Cell and Developmental Biology, The Hebrew University of Jerusalem, Israel.

    Prof. Edit Y. Tshuva – Institute of Chemistry, The Hebrew University of Jerusalem, Israel.